FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (BeyondSpring or the Company), a clinical-stage global biopharmaceutical company focused on developing...
Debiopharm has dosed the first patient in a Phase I clinical trial of Debio 0123 combined with carboplatin and etoposide to treat recurrent or progressive small cell lung cancer (SCLC) in patients following a standard platinum-based chemotherapy.
WILMINGTON, Del.--(BUSINESS WIRE)--Updated results from the CASPIAN Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Privately-held US firm H2-Pharma has entered into an agreement with Germany’s Cheplapharm Arzneimittel to be the exclusive US distributor of Etopophos (etoposide phosphate) for injection.nnThis opportunity arose due to its successful partnership with Cheplapharm, which has recently completed its acquisition of Etopophos from Bristol-Myers Squibb
AstraZeneca recently reported positive interim data from clinical trials of two, and potentially a third, of its drugs for cancer. As promising as that data looks, they will face an increasingly complicated and competitive market for both checkpoint inhibitors and BTK inhibitors. Here’s a look.
Bristol-Myers Squibb's FDA approval for Opdivo in patients with previously treated small cell lung cancer (SCLC) already has looked shaky since the drug failed to extend patients' lives in a phase 3 trial. Now, Opdivo will have to make some room for its archrival, Merck & Co.’s Keytruda, in the same indication.
Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P., in conjunction with Mundipharma EDO GmbH, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its investigational drug etoposide toniribate, a novel topoisomerase II inhibitor, for the treatment of relapsed refractory biliary tract cancer.
Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3
Mylan Lab`s Etoposide Receives Approval In US